Session Information
Date: Monday, November 9, 2026
Title: (1035-1049) Rheumatoid Arthritis - Translational Models and Mechanisms Poster B
Session Type: Poster Session B
Session Time: 10:30AM-12:30PM
Background/Purpose: Rheumatoid arthritis (RA) is characterized by synovial inflammation and joint damage. Cytokine-rich autologous serum (ACRS) is used in regenerative musculoskeletal approaches, but its anti-inflammatory activity in RA is unclear. Human organ-on-a-chip systems may model joint tissue responses and screen patient-derived interventions. We aimed to validate two human joint-on-a-chip platforms, comprising cartilage-on-a-chip and synovium-on-a-chip models, to assess the safety and anti-inflammatory effects of RA-derived ACRS under basal and TNFα-stimulated conditions
Methods: ACRS samples were obtained from a parent RA cohort stratified by age at onset, serostatus, and disease activity. For joint-on-a-chip experiments, samples from 12 seropositive patientsrepresenting 4 phenotypes were tested: elderly-onset RA in remission, elderly-onset inflammatory RA, young-onset RA in remission, and young-onset inflammatory RA (3 patients/group). Human cartilage-on-a-chip and synovium-on-a-chip models were generated in a microfluidic device using human chondrocytes and synoviocytes under basal and TNFα-stimulated conditions (Figure 1). ACRS was tested in both models and compared with glucocorticoids. Safety was assessed by bright-field microscopy and Alamar Blue assays. Anti-inflammatory effects were assessed through IL-6 quantification by ELISA. Group comparisons used t tests for statistical analysis.
Results: ACRS did not induce cytotoxicity in either cartilage-on-a-chip or synovium-on-a-chip models. Under TNFα stimulation, ACRS reduced IL-6 secretion in cartilage-on-a-chip when derivedfrom elderly-onset RA in remission, young-onset RA in remission, and young-onset inflammatory RA (all p < 0.05), with effects comparable to glucocorticoids (Figure 2A). In synovium-on-a-chip, ACRS from elderly-onset and young-onset RA in remission prevented TNFα-induced IL-6 upregulation (p < 0.05), whereas glucocorticoids did not show a significant anti-inflammatory effect in this model (Figure 2B). Under basal conditions, ACRS did not trigger inflammatory responses, supporting an in vitro safety profile (Figure 2A-B).
Conclusion: Human cartilage-on-a-chip and synovium-on-a-chip platforms enabled the evaluation of RA patient-derived ACRS in biologically relevant inflammatory environments. ACRS showed anin vitro safety profile and reduced TNFα-induced IL-6 secretion in a tissue- and donor phenotype-dependent manner, with differential effects compared with glucocorticoids. Thesefindings support joint-on-a-chip systems as translational platforms for preclinical therapeutic screening and provide a framework for developing personalized anti-inflammatory and regenerative strategies in RA. Larger studies with expanded samples and additional molecular readouts are warranted.
Figure 1A. Cell culture configuration in the Joint-on-a-Chip model. Figure 1B. Long-term perfusion and cell monitoring in the Joint-on-a-Chip. Figure 1C. Cell viability assessment in the CoC and SoC models using Alamar Blue.
Figure 2A. Cartilage-on-a-chip model used to study the safety and efficacy of ACRS treatments. Representative bright-field microscopy images are shown in the upper panel. Cell viability assessed by Alamar Blue assay is presented in the lower left panel. IL-6 ELISA results are shown in the lower right panel. Standard deviation was calculated for each group and is displayed in the graphs. Statistical analysis was performed using a t-test. * p =≤ 0.05 comparing non-senescent (untreated) vs senescent (TNFα). # p =≤ 0.05 comparing senescent (TNFα) vs corticosteroid- and ACRS-treated groups (purple). Figure 2B. Synovium-on-a-chip model used to study the safety and efficacy of ACRS treatments. Representative bright-field microscopy images are shown in the upper panel. Cell viability assessed by Alamar Blue assay is presented in the lower left panel. IL-6 ELISA results are shown in the lower right panel. Standard deviation was calculated for each group and is displayed in the graphs. Statistical analysis was performed using a t-test. * p =≤ 0.05 comparing non-senescent (untreated) vs senescent (TNFα). # p =≤ 0.05 comparing senescent (TNFα) vs corticosteroid- and ACRS-treated groups (purple).
To cite this abstract in AMA style:
Eyre Olmos C, Planas Rigol E, Cabot Canyelles J, Julià Agulló G, De Luna Salvà N, Gomez Centeno A, García Manrique De Lara M, Rusiñol González M, Garcia Pinilla A, Piqué Menéndez C, Cabanillas Paredes M, Feliu Hernàndez C, Carreras-Nolla A, Rodrigo-Parés A, Fuentes Palacios D, Saus Martínez E, Montero Molina S, Noguera Ferrer N, Dulsat Mas J, Arqué Corredor À, Calvet Fontova J, Graell Martín E. A Human Joint-on-a-Chip Platform Reveals Anti-inflammatory Effects of Cytokine-Rich Autologous Serum Derived from Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/a-human-joint-on-a-chip-platform-reveals-anti-inflammatory-effects-of-cytokine-rich-autologous-serum-derived-from-patients-with-rheumatoid-arthritis/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-human-joint-on-a-chip-platform-reveals-anti-inflammatory-effects-of-cytokine-rich-autologous-serum-derived-from-patients-with-rheumatoid-arthritis/
